

Comparison of Irinotecan and Oxaliplatin as the First-Line Therapies for Metastatic Colorectal Cancer: A Meta-analysis

Sadayuki Kawai (✉ sadayuki-kawai@i.shizuoka-pho.jp)

Shizuoka General Hospital <https://orcid.org/0000-0001-6815-6261>

Nozomi Takeshima

Kitabayashi Hospital

Yu Hayasaka

Tsukuba Psychosomatics Clinic

Akifumi Notsu

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Mutsumi Yamazaki

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Takanori Kawabata

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Kentaro Yamazaki

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Keita Mori

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Hirofumi Yasui

Shizuoka Cancer Center: Shizuoka Kenritsu Shizuoka Gan Center

Research article

Keywords: meta-analysis, metastatic colorectal cancer, chemotherapy

Posted Date: October 16th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-72198/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on February 4th, 2021. See the published version at <https://doi.org/10.1186/s12885-021-07823-7>.

Abstract

Background

Irinotecan (IRI) and oxaliplatin (Ox) are standard therapeutic agents of the first-line treatments for metastatic colorectal cancer (mCRC). Previous meta-analyses of randomized controlled trials (RCTs) showed that treatment with Ox-based compared with IRI-based regimens was associated with better overall survival (OS). However, these reports did not include trials of molecular targeting agents and did not take methods for the administration of concomitant drugs, such as bolus or continuous infusion of 5-fluorouracil, into account. A systematic literature review was performed to compare the efficacy and toxicity profiles between IRI- and Ox-based regimens as the first-line treatments for mCRC.

Methods

This meta-analysis used data from the Cochrane Central Register of Controlled Trials, PubMed, and SCOPUS. The primary endpoint was OS, and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs).

Results

Nineteen trials involving 4,571 patients were included in the analysis. No statistically significant difference was observed between the two groups in terms of OS, PFS, and ORR. There was no significant heterogeneity. Regarding \geq grade 3 AEs, IRI-based regimens were associated with a high incidence of leukopenia, febrile neutropenia, and diarrhea. Moreover, there was a high incidence of thrombocytopenia and peripheral sensory neuropathy in patients who received Ox-based regimens. In a subgroup analysis, IRI combined with bevacizumab was correlated with a better PFS (HR = 0.90, 95% CI = 0.82–0.98, P = 0.02), but not with OS.

Conclusion

Although the safety profiles of IRI- and Ox-based regimens varied, their efficacy did not significantly differ. Therefore, both regimens could be used as the first-line treatments for mCRC with consideration of the patients' condition or toxicity profiles.

Background

Currently, colorectal cancer (CRC) ranks fourth for incidence worldwide, with 550,000 deaths recorded annually.¹ Patients with unresectable metastatic CRC (mCRC) have a poor prognosis, with a median overall survival (OS) of 6–8 months, without any therapy. Although chemotherapy is the standard treatment for these patients, the median OS is only 20–25 months.²

The combination of cytotoxic and molecular targeting agents is currently used as the first-line treatment for patients with unresectable mCRC. Irinotecan (IRI) or oxaliplatin (Ox) combined with fluoropyrimidines (FPs) is considered as the backbone of cytotoxic agents for the treatment of mCRC.³ In the meta-analysis conducted by Grothey et al.⁴, the use of all three active drugs (FPs, IRI, and Ox) for mCRC was associated with a long OS.

First-line treatment is important for patients with mCRC, because the treatment period is the longest of the overall treatment time and significantly affects survival and quality of life (QOL). With regard to the use of cytotoxic agents, several trials investigated the best combination of regimens. Tournigand et al.⁵ and Colucci et al.⁶ conducted clinical trials to compare the efficacy between 5-fluorouracil (5-FU), folinic acid, and Ox (FOLFOX) regimen and 5-FU, folinic acid, and IRI (FOLFIRI) regimen. Results showed no significant differences between the two regimens. Moreover, Yamazaki et al.⁷ compared these regimens with bevacizumab (BEV), a molecular targeting agent. Results showed that the OS did not significantly differ between patients who received FOLFOX + BEV and FOLFIRI + BEV. Hence, both IRI- and Ox-based regimens could be used as the first-line treatments for mCRC.

In clinical practice, physicians generally select the regimen based on adverse events (AEs) caused by the drugs or the patients' condition. Recent reports showed that physicians preferred Ox-based regimen than IRI-based regimen. Field et al.⁸ conducted a survey on the use of chemotherapy for CRC. Results showed that 92.6% of medical oncologists in Australia select Ox-based regimen as the first-line treatment. They reported physicians commonly select this regimen as it has better efficacy and lower toxicity than IRI-based regimen. In addition, Marschner et al.⁹ conducted a prospective cohort study and revealed that Ox-based regimen was used as the first-line treatment in 430 out of 605 patients (71.0%) with mCRC.

Previous meta-analyses¹⁰⁻¹² of the first-line treatments for mCRC revealed that Ox-based regimen was correlated with a better OS. However, these studies included trials comparing continuous 5-FU infusion regimen with bolus 5-FU regimen, which is currently considered an inferior method. Moreover, these data were obtained from reports of regimens without molecular targeting agents. Therefore, they might not be applicable in the current clinical practice. Recently, a population-based observational study conducted by Teng et al.¹³ reported that IRI-based regimen might be more effective in improving OS than Ox-based regimen. Therefore, it remains unclear which regimen is associated with a better OS. Thus, a meta-analysis based on the current knowledge was performed to compare the efficacy and toxicity between IRI- and Ox-based regimens as the first-line treatments for mCRC.

Methods

Search Strategy and Selection Criteria

We searched PubMed, SCOPUS, and the Central Registry of Controlled Trials of the Cochrane Library (CENTRAL) without language restrictions. The last search update was performed on December 17, 2018. The inclusion criteria were as follows: (1) randomized controlled trials comparing IRI- and Ox-based combination regimens as the first-line treatments for mCRC and (2) those using similar agents (IRI- or Ox-based combination regimens) or agents with comparable efficacy based on the results of previous randomized controlled trials. The efficacy of oral FPs was similar to that of continuous infusion of 5-FU. That is, capecitabine + Ox (CapOx) regimen and S-1 + Ox (SOX) regimen were considered as alternative to FOLFOX regimen.¹⁴⁻¹⁶ Similarly, capecitabine + IRI (CapIRI) and S-1 + IRI (IRIS) regimens were considered as alternative to FOLFIRI regimen.^{17, 18} (3) Abstracts or unpublished data were included if they had sufficient information on study design, characteristics of participants, interventions, and outcomes.

The search terms used were as follows: (1) terms suggestive of “colorectal” (i.e., “colorect*,” “colon,” “colonic,” “bowel*,” “recta*,” or “rectum”), (2) “cancer” (i.e., “cancer,” “carcinoma*,” “neoplas*,” or “tumor”), (3) “irinotecan” (i.e., “irinotecan,” “camptotecin-11,” or “topotecin”), (4) “oxaliplatin” (i.e., “L-OHP,” “eloxatine,” or “oxaliplatin”), and (5) “randomized trials” (i.e., “ramdomized controlled,” “randomised,” or “randomly”).

Data Extraction

At least two of three review authors (SK, NT, and YH) independently scanned titles and abstracts to exclude studies that do not meet the criteria. The full text reports were then reviewed for further assessment. Disagreements were resolved via a consensus. Detailed data from eligible trials, such as year of publication, place where the study was conducted, study design, regimens, participants’ information, methodological evaluation, outcomes, and AEs, were extracted. If necessary, the authors were contacted for clarifications.

Assessment of Risk of Bias

At least two of three authors (SK, NT, and YH) independently assessed the risk of bias in the included studies in accordance with the Cochrane Handbook for Systematic Reviews of Interventions.¹⁹ The following domains were assessed: (1) sequence generation; (2) allocation concealment; (3) blinding of participants, personnel, and outcome assessors; (4) incomplete outcome data; (5) selective outcome reporting; and (6) other potential threats to validity. When inadequate details of methodological characteristics of trials were provided, the authors were contacted to obtain further information.

Statistical Analysis

The primary endpoint was OS. The secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and \geq grade 3 AEs according to the Common Terminology Criteria for Adverse Events version 4.0. Hazard ratios (HRs) and 95% confidence interval (CI), which were considered as relevant effect measures, were directly or indirectly assessed using the given data. When the Kaplan–Meier curve, but not the HR for PFS or OS, was included, we extracted the value using the Engauge Digitizer 10.8 and the method provided by Tierney et al.²⁰ ORR were compared using odds ratio (OR). The risk difference was used to compare the risk of AEs. Statistical heterogeneity among the studies was assessed using the chi-square test and was expressed with the I^2 index.¹⁹ The pooled effect was calculated with the random-effects model. Subgroup analyses were performed according to the combination of agents, which include regimens with or without molecular targeting agents, infusion of 5-FU or oral FPs, and anti-epidermal growth factor receptor (EGFR) or anti-ca (VEGF) antibodies. Since a previous report showed that CapOx plus anti-EGFR antibody might be less effective than FOLFOX plus anti-EGFR,²¹ we added the subgroup of anti-EGFR antibodies except CapOx + cetuximab. Statistical analyses were performed using the RevMan 5.3 software, which was provided by The Cochrane Collaboration. The corresponding funnel plots were used to examine the effect of publication bias visually. A two-sided P -value < 0.05 was considered statistically significant.

Results

Search Results and Characteristics of the Included Trials

A total of 4,451 potentially relevant studies were retrieved from the initial database search in PubMed, SCOPUS, and CENTRAL. Of these studies, 22 met all the inclusion criteria. However, one trial did not provide sufficient data,²² and two were discontinued early due to poor accrual.^{23, 24} Finally, 19 RCTs^{5-7, 25-40} with 4,571 patients were included in the analysis. A flowchart of the search process is shown in Fig. 1.

Table 1 shows the characteristics of RCTs included in the meta-analysis. Of these, 12 trials (n = 3,534) used 5-FU infusion regimens; 6 (n = 943), oral FPs; and 1, raltitrexed (n = 94). Nine RCTs (n = 2,154) used regimens with molecular targeting agents. Among them, five used BEV and four anti-EGFR antibodies (cetuximab or panitumumab). In total, 2 RCTs were conducted in North America, 13 in Europe, and 4 in Asia. The median age of the participants in all studies was 61–75 years. In one trial³², only elderly patient aged > 70 years was eligible.

Table 1
 Characteristics of randomized controlled trials included in the meta-analysis.

Study no.	Authors	Region	Year	Trial phase	Primary endpoint	Interventions	Patients	Median OS (months)
1	Grothey et al. ²⁵	USA	2003	2	AEs	CapOx CapIRI	82 79	NA NA
2	Tournigand et al. ⁵	France	2004	3	PFS	FOLFOX FOLFIRI	113 113	20.6 21.5
3	Kalofonos et al. ²⁶	Greece	2005	2	ORR	Weekly Ox + LV + 5-FU Weekly IRI + LV + 5-FU	148 147	17.4 17.6
4	Comella et al. ²⁷	Italy	2005	3	ORR	OXAFAFU IRIFAFU	140 133	18.9 15.6
5	Colucci et al. ⁶	Italy	2005	3	ORR	FOLFOX FOLFIRI	182 178	15 14
6	Feliu et al. ²⁸	Spain	2005	2	ORR	Raltitrexed + Ox Raltitrexed + IRI	48 46	NA NA
7	Zheng et al. ²⁹	China	2006	2	ORR	FOLFOX7 FOLFIRI	30 30	NA NA
8	Bajetta et al. ³⁰	Italy	2007	2	AEs	TEGAFOX TEGAFIRI	73 68	19 20
9	Seymour et al. ³¹	UK	2007	3	OS	OxFU IrFU	357 356	15.4 16.7
10	Rosati et al. ³²	Italy	2010	2	ORR	CapOx CapIRI	47 47	19.3 14
11	Ocvirk et al. ³³	Germany Austria	2010	2	PFS	FOLFOX6 + Cmab FOLFIRI + Cmab	77 74	17.4 18.9
12	Moosmann et al. ³⁴	Germany	2011	2	ORR	CapOx + Cmab CapIRI + Cmab	92 93	25.5 21.1
13	Schmiegel et al. ³⁵	Germany	2013	2	PFS	CapOx + BEV CapIRI + BEV	127 128	24.4 25.5
14	Folprecht et al. ³⁶	Germany Austria	2014	2	ORR	FOLFOX6 + Cmab FOLFIRI + Cmab	56 55	35.8 29
15	Yamazaki et al. ⁷	Japan	2016	3	PFS	FOLFOX6 + BEV FOLFIRI + BEV	200 202	30.4 31.4
16	Parikh et al. ³⁷	USA	2018	2	PFS	FOLFOX6 + BEV FOLFIRI + BEV	188 188	23.9 27.5

17	Carrato et al. ³⁸	Spain	2017	2	ORR	FOLFOX4 + Pmab FOLFIRI + Pmab	40 40	37 41
18	Yamada et al. ³⁹	Japan	2018	3	PFS	FOLFOX(CapOx) + BEV S-1+IRI + BEV	244 243	33.6 34.8
19	Nakayama et al. ⁴⁰	Japan	2018	2	ORR	CapOx + BEV CapIRI + BEV	54 53	26.7 28.7
<p>OS, overall survival; AEs, adverse events; PFS, progression-free survival; ORR, objective response rate; NA, not available; CapOx, capecitabine + Ox; CapIRI, capecitabine + IRI; FOLFOX and OXAFUFU, 5-FU + folinic acid + Ox; FOLFIRI and IRIFAFU, 5-FU + folinic acid + IRI; TEGAFUX, tegafur + folinic acid + Ox; TEGAFIRI, tegafur + folinic acid + IRI; BEV, bevacizumab; Cmab, cetuximab; and Pmab, panitumumab</p>								

Efficacy and Toxicity

Sixteen trials included data on OS (Fig. 2A). Since seven RCTs did not describe the HR for OS, we estimated the value using the Kaplan–Meier curve. Results showed no significant difference between IRI- and Ox-based regimens (pooled HR = 0.96, 95% CI = 0.89–1.03, $P = 0.28$), and there was no significant heterogeneity among the trials ($I^2 = 2\%$). Thirteen trials included data on PFS (Fig. 2B). We estimated the HR for PFS in six trials using the Kaplan–Meier curve. No significant difference was observed between the two groups (pooled HR = 0.98, 95% CI = 0.94–1.04, $P = 0.49$), and there was no significant heterogeneity ($I^2 = 0\%$). All trials included data on ORR (Fig. 2C). There was no significant difference between the two groups. However, Ox-based regimen had a favorable outcome (pooled OR = 1.13, 95% CI = 1.00–1.27, $P = 0.06$). No significant heterogeneity was observed ($I^2 = 0\%$).

We then performed a subgroup analysis according to the combination regimens. Overall, the OS did not significantly differ between IRI- and Ox-based regimens in all subgroups (Fig. 3A). The combined therapy of IRI and anti-VEGF was associated with a better PFS (pooled HR = 0.90, 95% CI = 0.82–0.98, $P = 0.02$), but not with OS (pooled HR = 0.91, 95% CI = 0.80–1.03, $P = 0.15$) (Fig. 3B and 3A). Ox-based regimens, especially those without molecular targeting agents, were associated with a better ORR (pooled OR = 1.22, 95% CI = 1.03–1.45, $P = 0.02$) (Fig. 3C).

The incidence of any \geq grade 3 AEs did not significantly differ between patients who received the two regimens. Thrombocytopenia, peripheral sensory neuropathy, hand–foot syndrome, and allergic reaction were significantly correlated with Ox-based regimens. Meanwhile, leukopenia, diarrhea, and febrile neutropenia were commonly observed in patients who received IRI-based regimens (Fig. 4).

Assessment of Risk of Bias

Risk of bias assessment is shown in Fig. 5. Overall, the quality of evidence in this study was moderate according to the risk of bias assessment (Fig. 5A). The funnel plot of each effect size in terms of OS, PFS, and ORR was symmetrical, with a similar number of studies on either side of the summary treatment effect. This result indicated a lack of major publication bias (Fig. 5B).

Discussion

Based on the current expert panels of guidelines^{3,41,42}, there is no preferred regimen that can be used as the initial therapy for mCRC. Hence, IRI- or Ox-based regimen can be an alternative. In clinical practice, the regimen is selected based on efficacy of the regimens, physicians' experience, and profiles of AEs.

Our analysis showed that there was no significant difference in terms of OS between patients who received IRI- and Ox-based regimens as the first-line treatments for mCRC. This is the first meta-analysis that included treatments containing molecular targeting agents and clinically comparable combination of regimens. Therefore, the results of this study may be more applicable to current clinical practice than those of previous studies. The absence of significant heterogeneity between trials in terms of OS, PFS, and ORR indicated consistent results. Previous reports¹⁰⁻¹² showed that Ox-based regimen was more preferred in terms of OS. This discrepancy in results may be attributed to the selection criteria of the trials. That is, previous studies included trials comparing FOLFOX with IFL (bolus 5-FU + IRI) regimen.^{43,44} However, Delaunoy et al.⁴⁵ showed that bolus 5-FU + IRI or Ox could be associated with severe gastrointestinal toxicity and high mortality rates. Thus, excluding these trials was appropriate for the evaluation of efficacy and toxicity between the two regimens.

In the subgroup analysis of regimens without molecular targeting agents, Ox-based regimen was associated with a better ORR. However, the PFS and OS did not significantly differ. In colorectal cancer, the correlation between ORR and OS is not clearly elucidated.⁴⁶ Hence, our results were not conflicting. In addition, in this subgroup, six of ten trials^{6,26-29,32} used ORR as the primary endpoint, and four^{6,27,29,32} studies hypothesized that Ox-based regimen is associated with a better ORR. Thus, the evaluation of ORR might be biased in these trials.

In the subgroup analysis of regimens with molecular targeting agents, the combination of anti-VEGF antibody and IRI was more likely to be associated with better PFS and OS. However, the synergic effect of IRI and anti-VEGF antibody had not been reported. Although these data were mainly obtained from Japanese trials^{7,39,40}, no data have shown that the combination was more beneficial for Japanese patients. Therefore, we speculated that this result was obtained by chance and was not clinically significant.

With regard to the results of AEs, the incidence of \geq grade 3 AEs did not significantly differ between patients who received the two regimens. Therefore, it may be reasonable for physicians to select each regimen according to AE profiles. However, Yamazaki et al.⁷ revealed that the FACT-C QOL score was more likely worse in patients treated with FOLFOX + BEV than in those treated with FOLFIRI + BEV. Moreover, a previous report indicated that peripheral sensory neuropathy lasts for a long period and affects QOL after treatment.⁴⁷ Thus, physicians should consider QOL during not only the first-line treatment but also the overall survival time when selecting the regimens.

This study had some limitations. That is, it is a meta-analysis. Moreover, there were no data on race, sex, primary site of the tumor, and status of *RAS* and *BRAF* genes. Thus, our data must be applied with caution to individual patients in clinical practice. Recently, some reports showed that the molecular subtypes or

chromosomal variation of CRC might affect the efficacy of IRI- and Ox-based regimens.^{48, 49} Thus, in the future, suitable cytotoxic agents should be selected according to biomarker profile.

Conclusions

The efficacy of IRI- and Ox-based regimens when used as the first-line treatments for mCRC did not significantly differ. Hence, both regimens could be used in clinical practice with consideration of the patients' condition or toxicity profiles.

Abbreviations

IRI, irinotecan; Ox, oxaliplatin; mCRC, metastatic colorectal cancer; RCT, randomized controlled trial; OS, overall survival; PFS, progression free survival; ORR, objective response rate; AEs, adverse events; HR, hazard ratio; FPs, fluoropyrimidines; QOL, quality of life; CENTRAL, the Central Registry of Controlled Trials of the Cochrane Library; CI, confidence interval; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; CapOx, capecitabine + oxaliplatin; CapIRI, capecitabine + irinotecan; IFL, bolus 5-FU + irinotecan, 5-FU, 5-fluorouracil; BEV, bevacizumab; IRIS, S-1 + irinotecan, FOLFOX and OXAFUFU, 5-FU + folinic acid + oxaliplatin; FOLFIRI and IRIFAFU, 5-FU + folinic acid + irinotecan; TEGAFUX, tegafur + folinic acid + oxaliplatin; TEGAFIRI, tegafur + folinic acid + irinotecan; NA, not available; MTAs, molecular targeting agents

Declarations

Ethics approval and consent to participate

Not applicable. Ethical approval was not required for this study because this meta-analysis is literature based research and did not use individual data.

Consent for publication

Not applicable.

Competing interests

All authors declare no conflicts-of-interest related to this article.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Authors' contributions

Conceptualization and study design: SK, NT, YH, KY, AN, TK, KM, MY; Writing an original draft: SK; Project administration: YH, KY; Review and editing: SK, NT, YH, AN, MY, TK, KM, KY; Formal analysis: AN, TK, KM; Supervision: YH, KM, KY; Investigation of data: SK, NT, YH, MY; and All authors read and approved the final manuscript.

Acknowledgements

We would like to show our greatest appreciation to Dr. Goro Nakayama and Dr. Gerardo Rosati for providing data of their clinical trials.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Bray F, Ferlay J, Soerjomataram I, *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;**68**:394–424. doi:10.3322/caac.21492
2. Dekker E, Tanis PJ, Vleugels JLA, *et al.* Colorectal cancer. *Lancet* 2019;**394**:1467–80. doi:10.1016/S0140-6736(19)32319-0
3. NCCN Guidelines Colon Cancer Version 4. 2020, <https://www.nccn.org/>; Accessed 2 July 2020.
4. Grothey A, Sargent D, Goldberg RM, *et al.* Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. *J Clin Oncol.* 2004;**22**:1209–14. doi:10.1200/JCO.2004.11.037
5. Tournigand C, André T, Achille E, *et al.* FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol.* 2004;**22**:229–37. doi:10.1200/JCO.2004.05.113
6. Colucci G, Gebbia V, Paoletti G, *et al.* Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol.* 2005;**23**:4866–75. doi:10.1200/JCO.2005.07.113
7. Yamazaki K, Nagase M, Tamagawa H, *et al.* Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). *Ann Oncol.* 2016;**27**:1539–46. doi:10.1093/annonc/mdw206
8. Field KM, Kosmider S, Jefford M, *et al.* Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? *J Oncol Pract.* 2008;**4**:271–6. doi:10.1200/JOP.0852002
9. Marschner N, Arnold D, Engel E, *et al.* Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. *Clin Epidemiol.* 2015;**7**:295–303. doi:10.2147/CLEP.S73857

10. Liang XB, Hou SH, Li YP, *et al.* Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. *Chin Med J.* 2010;**123**:3314–8.
11. Golfopoulos V, Salanti G, Pavlidis N *et al.* Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. *Lancet Oncol.* 2007;**8**:898–911. doi:10.1016/S1470-2045(07)70281-4
12. Zhuang L, Bai J, Huang H, *et al.* Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer. *Oncol Res.* 2010;**18**:437–44. doi:10.3727/096504010x12671222663511
13. Teng CL, Wang CY, Chen YH, *et al.* Optimal sequence of irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer: a population-based observational study. *PLoS One.* 2015;**10**:e0135673. doi:10.1371/journal.pone.0135673
14. Cassidy J, Clarke S, Díaz-Rubio E, *et al.* Randomized phase III study of Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol.* 2008;**26**:2006–12. doi:10.1200/JCO.2007.14.9898
15. Hong YS, Park YS, Lim HY, *et al.* S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. *Lancet Oncol.* 2012;**13**:1125–32. doi:10.1016/S1470-2045(12)70363-7
16. Yamada Y, Takahari D, Matsumoto H, *et al.* "Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol.* 2013;**14**:1278–86. doi:10.1016/S1470-2045(13)70490-X
17. Fuchs CS, Marshall J, Mitchell E *et al.* Randomized, controlled trial of irinotecan plus Infusional, bolus, or oral Fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. *J Clin Oncol.* 2007;**25**:4779–86. doi:10.1200/JCO.2007.11.3357
18. Muro K, Boku N, Shimada Y, *et al.* Irinotecan Plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS Study). *Lancet Oncol.* 2010;**11**:853–60. doi:10.1016/S1470-2045(10)70181-9
19. Higgins JPT, Thomas J, Chandler J, *et al.* *Cochrane handbook for systematic reviews of interventions*, 2nd Edition, 2019
20. Tierney JF, Stewart LA, Ghersi D, *et al.* Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;**8**:16. doi:10.1186/1745-6215-8-16
21. Maughan TS, Adams RA, Smith CG, *et al.* Addition of Cetuximab to Oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet.* 2011;**377**:2103–14. doi:10.1016/S0140-6736(11)60613-2
22. Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer (PASSION), <https://clinicaltrials.gov/ct2/show/NCT02119026>. Accessed 2 July 2020.
23. FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum. <https://clinicaltrials.gov/ct2/show/NCT00077233>. Accessed 2 July 2020.

24. IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer. <https://clinicaltrials.gov/ct2/show/NCT00316745>. Accessed 2 July 2020.
25. Grothey A, Jordan K, Kellner O, *et al.* Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. *EJC Supplements*; 2003; **1**: S90-S91. doi:10.1016/S1359-6349(03)90328-4
26. Kalofonos HP, Aravantinos G, Kosmidis P, *et al.* Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. *Ann Oncol.* 2005;**16**:869–77. doi:10.1093/annonc/mdi193
27. Comella P, Massidda B, Filippelli G, *et al.* Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFUFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. *Ann Oncol.* 2005;**16**:878–86. doi:10.1093/annonc/mdi185
28. Feliu J, Castañón C, Salud A, *et al.* Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. *Br J Cancer* 2005;**93**:1230–5. doi:10.1038/sj.bjc.6602860
29. Zheng H, Chen JZ, Liao WJ, *et al.* Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer. *Nan Fang Yi Ke Da Xue Xue Bao.* 2006;**26**:689–91.
30. Bajetta E, Di Bartolomeo M, Buzzoni R, *et al.* Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. *Br J Cancer.* 2007;**96**:439–44. doi:10.1038/sj.bjc.6603493
31. Seymour MT, Maughan TS, Ledermann JA, *et al.* Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet.* 2007;**370**:143–52. doi:10.1016/S0140-6736(07)61087-3
32. Rosati G, Cordio S, Bordonaro R, *et al.* Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. *Ann Oncol.* 2010;**21**:781–6. doi:10.1093/annonc/mdp359
33. Ocvirk J, Brodowicz T, Wrba F, *et al.* Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. *World J Gastroenterol.* 2010;**16**:3133–43. doi:10.3748/wjg.v16.i25.3133
34. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, *et al.* Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. *J Clin Oncol.* 2011;**29**:1050–8. doi:10.1200/JCO.2010.31.1936
35. Schmiegel W, Reinacher-Schick A, Arnold D, *et al.* Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. *Ann Oncol.* 2013;**24**:1580–7. doi:10.1093/annonc/mdt028
36. Folprecht G, Gruenberger T, Bechstein W, *et al.* Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). *Ann Oncol.* 2014;**25**:1018–25. doi: 10.1093/annonc/mdu088

37. Parikh AR, Lee FC, Yau L, *et al.* MAVERICC, a randomized, biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab Versus FOLFIRI-Bevacizumab as first-line chemotherapy in metastatic colorectal cancer. *Clin Cancer Res.* 2019;**25**:2988–95. doi: 10.1158/1078-0432.CCR-18-1221
38. Carrato A, Abad A, Massuti B, *et al.* First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). *Eur J Cancer.* 2017;**81**:191–202. doi: 10.1016/j.ejca.2017.04.024
39. Yamada Y, Denda T, Gamoh M, *et al.* S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. *Ann Oncol.* 2018;**29**:624–31. doi:10.1093/annonc/mdx816
40. Nakayama G, Mitsuma A, Sunagawa Y, *et al.* Randomized phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as first-Line treatment for Japanese Patients with metastatic colorectal cancer (CCOG-1201 Study). *Oncologist.* 2018;**23**:919–27. doi:10.1634/theoncologist.2017-0640
41. Van Cutsem E, Cervantes A, Adam R, *et al.* ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol.* 2016;**27**:1386–422. doi:10.1093/annonc/mdw235
42. Yoshino T, Arnold D, Taniguchi H, *et al.* Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol.* 2018;**29**:44–70. doi:10.1093/annonc/mdx738
43. Goldberg RM, Sargent DJ, Morton RF, *et al.* A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol.* 2004;**22**:23–30. doi:10.1200/JCO.2004.09.046
44. Goldberg RM, Sargent DJ, Morton RF, *et al.* Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. *J Clin Oncol.* 2006;**24**:3347–53. doi:10.1200/JCO.2006.06.1317
45. Delaunoy T, Goldberg RM, Sargent DJ, *et al.* Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. *Cancer.* 2004;**101**:2170–6. doi:10.1002/cncr.20594
46. Johnson KR, Ringland C, Stokes BJ, *et al.* Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. *Lancet Oncol.* 2006;**7**:741–6. doi:10.1016/S1470-2045(06)70800-2
47. Yoshino T, Yamanaka T, Oki E, *et al.* Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of Oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. *JAMA Oncol.* 2019;**5**:1574–81. doi:10.1001/jamaoncol.2019.2572
48. Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. *Lancet Oncol.* 2019;**20**:e274–e283. doi:10.1016/S1470-2045(19)30172-X
49. Fujita Y, Taguri M, Yamazaki K, *et al.* aCGH analysis of predictive biomarkers for response to Bevacizumab plus Oxaliplatin- or irinotecan-Based chemotherapy in patients with metastatic colorectal cancer. *Oncologist.* 2019;**24**:327–37. doi:10.1634/theoncologist.2018-0119

Figures

Fig. 1






Figure 1

Flowchart of the search process in randomized clinical trials (RCTs).

Fig. 2 A



B



C






Figure 2

Pooled analyses of each endpoint. Black dot at the left side represents the estimated hazard ratio obtained using the Kaplan–Meier curve. (A) Pooled analysis of overall survival (OS). (B) Pooled analysis of progression-free survival (PFS). (C) Pooled analysis of objective response rate (ORR). IRI, irinotecan; Ox, oxaliplatin; and CI, confidence interval

Fig. 3 A



B



C




Figure 3

Subgroup analyses according to combination regimens. (A) Pooled analysis of overall survival (OS). (B) Pooled analysis of progression-free survival (PFS). (C) Pooled analysis of objective response rate (ORR). IRI, irinotecan; Ox, oxaliplatin; MTAs, molecular targeting agents; CapOx, capecitabine plus oxaliplatin; C-mab, cetuximab; 5-FU, 5-fluorouracil; FPs, fluoropyrimidines; EGFR, epidermal growth factor receptor; and VEGF, vascular endothelial growth factor

Fig. 4





Figure 4

Risk difference in the incidence of \geq grade 3 AEs between patients who received IRI- and Ox-based regimens IRI, irinotecan; Ox, oxaliplatin



B




Figure 5

Assessment of risk of bias. (A) Risk of bias assessment for each included RCT. The bar chart indicates the distribution of risk-of-bias judgments across the domains. (B) The funnel plot of each effect size in terms of overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) SQ, sequence generation; AL, allocation concealment; BL, blinding; IN, incomplete outcome data; SL, selective outcome reporting; OT, other potential threats to validity; SE, standard error; HR, hazard ratio; OR, odds ratio

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMAchecklistBMC.doc](#)